financetom
Business
financetom
/
Business
/
CoreWeave’s All-Stock Bid for Core Scientific Likely to Draw Shareholder Scrutiny: KBW
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CoreWeave’s All-Stock Bid for Core Scientific Likely to Draw Shareholder Scrutiny: KBW
Jul 7, 2025 1:25 PM

CoreWeave ( CRWV ) has agreed to acquire bitcoin miner Core Scientific ( CORZ ) in an all-stock deal valued at $20.40 per share, implying a ~16x FY26E EBITDA multiple, a steep discount to traditional data center peers, according to investment bank KBW.

Core Scientific ( CORZ ) shares were 18% lower, trading around $14.75 at publication time. CoreWeave ( CRWV ) stock was down 5%.

While the deal offers CoreWeave ( CRWV ) strategic benefits, cutting over $10 billion in lease obligations and unlocking more than $500 million in annual cost savings by 2027, KBW views it as an opportunistic move, capitalizing on CRWV’s 295% post-IPO rally, the bank said in a report on Monday.

"While we view this as an opportunistic attempt by CRWV to capitalize on recent stock appreciation, the reaction signals disappointment and potential disagreement to the deal terms," wrote analyst Bill Papanastasiou.

Under the terms of the agreement, Core Scientific ( CORZ ) shareholders will receive 0.1235 CoreWeave ( CRWV ) shares for each share held, valuing the business at around $9 billion.

The deal requires approval from Core Scientific ( CORZ ) shareholders and is expected to close in Q4 2025.

Core Scientific ( CORZ ) shareholders may push back on the terms of the deal, the analyst noted, given the unchanged asset base since CRWV’s first failed bid and lack of a cash component. The "shareholder vote may see friction."

Still, with no competing offer expected, the deal is likely to proceed, the report said.

KBW has an "outperform" rating on Core Scientific ( CORZ ) shares with a $19 price target.

Rival Wall Street firm Bernstein noted the drop in the Core Scientific ( CORZ ) share price after the deal was announced and said "shareholders were probably expecting a higher valuation," and "investors were disappointed with an all stock deal."

The broker has an outperform rating on Core Scientific ( CORZ ) stock with a $17 price objective.

Read more: Core Scientific ( CORZ ), Bitcoin Miners Tumble on CoreWeave Buyout; Jefferies Says Price in Expected Range

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Amazon Insider Sold Shares Worth $4,586,006, According to a Recent SEC Filing
Amazon Insider Sold Shares Worth $4,586,006, According to a Recent SEC Filing
Feb 26, 2025
03:33 AM EST, 02/26/2025 (MT Newswires) -- Andrew R Jassy, Director, President and Chief Executive Officer, on February 21, 2025, sold 20,784 shares in Amazon ( AMZN ) for $4,586,006. Following the Form 4 filing with the SEC, Jassy has control over a total of 2,194,288 common shares of the company, with 2,118,886 shares held directly and 75,402 controlled indirectly....
Sterling Infrastructure Q4 Adjusted Earnings, Revenue Rise
Sterling Infrastructure Q4 Adjusted Earnings, Revenue Rise
Feb 26, 2025
03:38 AM EST, 02/26/2025 (MT Newswires) -- Sterling Infrastructure ( STRL ) reported late Tuesday Q4 adjusted earnings of $1.46 per diluted share, up from $1.29 a year earlier. Analysts polled by FactSet expected $1.33. Revenue for the quarter ended Dec. 31 was $498.8 million, up from $486 million a year earlier. Analysts polled by FactSet expected $531.3 million. The...
ZoomInfo Technologies Q4 Adjusted Net Income Flat, Revenue Decreases
ZoomInfo Technologies Q4 Adjusted Net Income Flat, Revenue Decreases
Feb 26, 2025
03:45 AM EST, 02/26/2025 (MT Newswires) -- ZoomInfo Technologies ( ZI ) reported Q4 adjusted net income late Tuesday of $0.26 per diluted share, the same as a year earlier. Analysts polled by FactSet expected $0.23. Revenue for the quarter ended Dec. 31 was $309.1 million, down from $316.4 million a year earlier. Analysts surveyed by FactSet expected $297.7 million....
India on the verge of becoming clinical trials hub, Parexel executive says
India on the verge of becoming clinical trials hub, Parexel executive says
Feb 26, 2025
By Bhanvi Satija and Kashish Tandon HYDERABAD (Reuters) - India is ready to step in as an alternative site for early-stage clinical trials to help mitigate the impact of disruptions such as the Russia-Ukraine war, an executive at contract research firm Parexel told Reuters on Wednesday. The U.S.-based company plans to boost its headcount in India by more than 2,000...
Copyright 2023-2026 - www.financetom.com All Rights Reserved